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DNA damage response pathwayChemoresistance prevents the curative cancer therapy, our understanding of which remains inadequate. Among
the differentially expressed genes between the chemosensitive (5637) and chemoresistant (H-bc) bladder
cancer cell lines, the expression level of the PSEN1 gene (presenilin 1), a key component of the γ-secretase, is
negatively correlatedwith chemoresistance. A small interfering RNAmediated repression of the PSEN1 gene sup-
presses cell apoptosis and de-sensitizes 5637 cells, while overexpression of the presenilin 1 sensitizes H-bc cells
to the drug-triggered cell death. As a direct target of microRNA-193a-3p that promotes the multi-
chemoresistance of the bladder cancer cell, PSEN1 acts as an important executor for the microRNA-193a-3p's
positive impact on themulti-chemoresistance of bladder cancer, probably via its activating effect onDNAdamage
response pathway. In addition to themechanistic insights, the key players in thismicroRNA-193a-3p/PSEN1 axis
are likely the diagnostic and/or therapeutic targets for an effective chemotherapy of bladder cancer.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Bladder cancer (BCa) is the world's second commonest type of
urogenital cancer in men [1,2]. Together with the high recurring rate,
BCa is highly refractory to drug therapy and regarded as one of the
most costly and difﬁcult types of cancer to be contained [3]. Although
an eradication of the primary lesions by chemotherapy is achieved in
about half of BCa patients, the disease often recurs, being refractory to
the 2nd round of chemotherapy [4], irrespective of the previous drugHCC, hepatocellular cancer; Pi,
in hydrochloride; Ci, cisplatin;
omerase reverse transcriptase;
dent kinase inhibitor 1A (p21,
eliosis viral oncogene homolog
, Anhui Cancer Hospital, Hefei,
nji Hospital, Shanghai Jiaotong
5897833, +86 21 64224285;exposure [5]. As a hallmark of cancer, the multi-chemoresistance varies
drastically among the cancer patients, the different cancer lesions or dif-
ferent regions of the same lesionswithin a single patient [6], presenting
one of the biggest challenges to both the effective chemo-resistance
prediction and the rational chemotherapy of cancer.
Despite years of intensive efforts, our knowledge of the multi-
chemoresistance of cancer remains poor [7–10]. The mechanisms in
discussion include an inefﬁcient cellular drug uptake and accumulation,
activation of the anti-oxidant glutathione system for detoxication,
enhancement of DNA repair, and up-regulation of anti-apoptosis path-
ways [11–13]. The best characterized genes involved in the multi-
chemoresistance of cancer are ATP-binding cassette (ABC) transporters,
such as P-glycoprotein (P-gp), breast cancer resistance proteins (BCRP)
andmutidrug resistance associated proteins (MRPs) [14–16], which are
often over-expressed in the multi-chemoresistant cancer cells [17].
In addition to the protein coding genes, the microRNA genes have a
vital role in the multi-chemoresistance of cancer [18]. For instance, we
showed in hepatocellular carcinoma (HCC) cells that the DNAmethyla-
tion regulated miR-193a-3p dictates the 5-FU resistance via repressing
SRSF2 expression [19]. We recently demonstrated the positive role of
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executed via its suppression of ﬁve direct targets: SRSF2, HIC2, PLAU,
LOXL4 and HOXC9 and in turn alter the activities of following ﬁve sig-
naling pathways: DNA damage response, Notch, NF-κB, Myc/Max and
oxidative stress [20–22].
For the protein coding genes that contribute to the BCa's multi-
chemoresistance, we performed a RNA-seq based-omic analysis for
the differentially expressed genes in between a multi-chemoresistant
(H-bc) and a multi-chemosensitive cell (5637) lines and found 9051
differentially expressed protein-coding genes (not shown). In thepreset
study, we systematically investigated both role and mechanisms of the
PSEN1 in the BCa multi-chemoresistance in both cultured cells and
tumor xenograft/nude mouse system. The PSEN1 (presenilin) is a key
component of a four protein entity, the γ-secretase complex that
catalyzes the intramembrane cleavage of integral membrane proteins
for the activation of Notch pathway [23]. The mutated PSEN1 gene has
been linked to the occurrence of the type III Alzheimer disease [24,25].
Relevant to its suppressing role in the BCa multi-chemoresistance,
PSEN1 expression positively correlates with the activity of DNA damage
response pathway. Furthermore, we showed that PSEN1 is a direct
target of miR-193a-3p and relays in a signiﬁcantly part the miR-193a-
3p's effect on the multi-chemoresistance.
2. Material and methods
2.1. Cell lines and transfection
Cell lines— 5637 (ATCCNO. HTB-9) and H-bc (established by cancer
research Institute of Kunming Medical College, 1986.) were purchased
from the Chinese Academy of Sciences Committee on Culture Collection
Cell Bank, Shanghai Institutes for Biological Sciences, Chinese Academy
of Cell Resource Center. Both cell lines are cultured in RPMI1640
(Invitrogen, USA) +10% fetal bovine serum (Invitrogen, USA) and 1%
glutamine at 37 °C in 5% CO2.
2.2. The mimic/antagomiR/siRNA/overexpression plasmid transfection
All the mimic, agomiR, antagomiR, siRNA and the scramble
sequence control (NC) as well as the ribo FECT CP transfection kit
were supplied by Guangzhou Ribobio, China). The mammalian ex-
pression constructs for PSEN1 (EX-G0389-M98-5) with GFP tag
were supplied by Guangzhou Fulengen, China. Transfection of both
ribonucleic acid reagents mentioned above and the reporter plasmids
in a Cignal Finder Pathway Reporter package (Qiangene, US) was
performed according to the manufacturer's instruction.
Chemically modiﬁedmimic oligonucleotides (agomir) were synthe-
sized to regulate miR-193a-3p/5p expression in vivo. The 3′ end of the
oligonucleotides was conjugated to cholesterol, and all the bases were
2′-OMe modiﬁed. The agomir oligonucleotides were deprotected,
desalted and puriﬁed by high-performance liquid chromatography.
2.2.1. Chemotherapeutics
All the chemotherapeutic drugs used are of the clinic grade [26,27]
(NCI Dictionary of Cancer Terms, http://www.cancer.gov/dictionary),
pirarubicin (Pi, Wanle, Shenzhen), paclitaxel (Pa, Taiji, Sichuan),
adriamycin (Ad, Pﬁzer, Jiangsu), epirubicin hydrochloride (EH, Haizheng,
Zhejiang), and cisplatin (Ci, Haosen, Jiangsu). The chemo-resistance
proﬁling (IC50 measurements) was conducted as previously described
[20].
2.3. Analysis of RNA
Total RNA was isolated using a TRIzol reagent (Tiangen Biotech Co.,
Ltd., Beijing, China). For mRNA analysis, the cDNA was made from
total RNA by oligo-dT priming with a prime Script RT reagent kit
(Tiangen Biotech Co., Ltd., Beijing, China) and the steady state mRNAlevel expression of PSEN1 was measured by qRT-PCR with gene-
speciﬁc ﬂuorescent Taqman probe together with the β-actin using a
differentially ﬂuorescence-labeled probe (provided by Shing Gene,
Shanghai, China) in the FTC-3000P (Funglyn Biotech Inc., Canada).
Using the 2−ΔΔ Ct method, the normalization with β-actin was
performed before each's relative level between 5637 and H-bc was cal-
culated (44). The primers and probes for complementary DNA synthesis
and qRT-PCR analysis are:
hPSEN1F: 5′-TATGGCAGAAGGAGACCCG-3′
hPSEN1R: 5′-CCATTCCTCACTGAACCCG-3′
hPSEN1 probe: 5′-CY5-CATTCTCTGCAACAGTGTCTTGTGACTCC-3′
hPSEN2 F: 5′-CTTCACTGATGCTGCTGTTCC-3′
hPSEN2 R: 5′-GAAGTTCCAGACAGTCAGCAAGA-3′
hPSEN2 probe: 5′-CY5-ACCTACAATGTGGCCATGGACTACCC-3′
hAPH1A F: 5′-TCGGTATCATCAGTGGTGTCTTC-3′
hAPH1A R: 5′-AAAGGTATGGAGCAGGATAATGG-3′
hAPH1A probe: 5′-CY5-CTTCCTGACTTCAGCCTTTCTGACAGC-3′
hCDKN1A F: 5′-CACTGTCTTGTACCCTTGTGCC-3′
hCDKN1A R: 5′-GGCTTCCTCTTGGAGAAGATCA-3′
hCDKN1A probe: 5′-ROX-CCCCAGGTGGACCTGGAGACTCTC-3′
hEDN1 F: 5′-CTTCTGCCACCTGGACATCA-3′
hEDN1 R: 5′-CATCTATTTTCACGGTCTGTTGC-3′
hEDN1 probe: 5′-ROX-CGTTGTTCCGTATGGACTTGGAAGCC-3′
hODC1 F: 5′-ATGATAGCAAAGCCATCGTGA-3′
hODC1 R: 5′-CCCAGACTCTGCACCAACTG-3′
hODC probe: 5′-ROX-CTACCGGGACAGGATTTGACTGTGC-3′
hTERT F: 5′-GCTGCTCAGGTCTTTCTTTTATG-3′
hTERT R: 5′-ACCTCTGCTTCCGACAGCTC-3′
hTERT probe: 5′-ROX-CGGAAGAGTGTCTGGAGCAAGTTGC-3′
hACTB F: 5′-GCCCATCTACGAGGGGTATG-3′
hACTB R: 5′-GAGGTAGTCAGTCAGGTCCCG-3′
hACTB probe: 5′HEX-CCCCCATGCCATCCTGCGTC-3′
2.4. Analysis of protein
Cells lysate with 1× SDS loading buffer (60 mM Tris–HCl, pH 6.8, 2%
SDS, 20% glycerol, 0.25% bromphenol blue, 1.25% 2-mercaptoethanol)
was heated at 100 °C for 10 min to facilitate the sample loading for
the conventional Western analysis. The anti-PSEN1 (AJ1650a), anti-α-
tubulin (AJ1034a) and anti-GAPDH (AM1020a) were provided by
Wuxi Phama, Shanghai, China. The target proteins were then probed
with anti-rabbit IgG peroxidase-conjugated antibody (LP1001b), or
HRP goat anti-mouse IgG antibody (LP1002a) (all antibodies are from
Abgent, San Diego, CA) followed by an enhanced chemiluminescence
reaction (Pierce). The relative levels of proteins were quantiﬁed using
densitometry with the Gel-Pro Analyzer (Media Cybernetics). The tar-
get bands over the GAPDH or α-tubulin band were densitometrically
quantiﬁed and indicated under each band.
2.5. Analysis of cell
2.5.1. Apoptosis analysis
Every group of cells was harvested and diluted with PBS twice. Then
5 μl of FITC-labeled enhanced-annexin V and 5 μl of 20 μg/ml of
propidium iodide were added to 100 μl cell. Upon incubation in the
dark for 15 min at room temperature, samples were diluted with
400 μl PBS. Flow cytometry was carried out on a FACSCalibur instru-
ment. The result was analyzed by random software. The experiments
were performed independently three times [28].
2.5.2. The luciferase reporter assay
A full length of the human PSEN1 3′-untranslated region
(1112 bp) with themiR-193a-3p targeting sequence (WT) or mutant
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luciferase gene in pGL3 (Invitrogen) to construct pGL3-luc-PSEN1.
All the constructs were conﬁrmed by restriction digestion. The lucif-
erase activity of 3′-UTR and pathway reporter assay was determined
as previously described [20].2.6. In vivo study
The xenograft model on nude mice was generated and analyzed
as previously described [20]. Expressions of PSEN1 protein were
measured using immunochemical analysis on 5-mm slices of forma-
lin ﬁxed parafﬁn-embedded tumor xenografts in nudemice. To avoid
inter-treatment bias, the tissue slides from different groups were
made on a single slide and subject to the same immuno-staining
simultaneously. Antigens were retrieved by pretreating dewaxed
sections in a microwave oven at 750 W for 5 min in a citrate buffer
(pH 6) processed with the Super sensitive link-labeled detection
system (Biogenex, Menarini, Florence, Italy). The enzymatic activi-
ties were developed using 3-amino-9-ethylcarbazole (Dako, Milan,
Italy) as a chromogenic substrate. Following counter staining with
Mayer hematoxylin (Invitrogen), slides were mounted in aqueous
mounting medium (glycergel, Dako). Pictures were taken using
LEICA DM 4000B microscope, while the relative level of each protein
was calculated using LEICA software, and the percentage of the mock
over the chemotherapeutic treated tumors was calculated and
plotted.Fig. 1. The PSEN1 expresses in a negative correlationwith chemoresistance in BCa cells. A, the PS
and the protein level (byWestern analysis) shown in both Table and plots (B, RNA level; C, prot
in the siRNA transfected versus theNC transfected 5637 cells. E, the relative cell survival in the 5
the IC50 dosed drugs. F, the PSEN1 protein level in the EGFP-PSEN1 transfected versus theGFP co
the H-bc cells transfected by an EGFP-PSEN1 over the GFP expression vectors, assayed at 72 h2.7. Statistical analysis
Data are presented as means, and error bars indicate the S.D. or S.E.
All statistical analyseswere performedwith Excel (Microsoft, Redmond,
WA) or Prism (GraphPad Software Inc., La Jolla, CA). Two-tailed
Student's t-test, a one-way analysis of variance or Mann–Whitney U
test was used to calculate statistical signiﬁcance. A P value of b0.05
was considered to be signiﬁcant.3. Results
3.1. PSEN1 is a negative regulator of the multi-chemoresistance of BCa
Among 9051 differentially expressed genes between a multi-
chemosensitive (5637) versus a resistant BCa cell line (H-bc) by the
RNA-seq based omic analysis, the PSEN1 gene (Fig. 1A) was selected
for further study. Its level was higher in 5637 than H-bc cells at both
protein (4.09:1, Fig. 1A and C) and mRNA levels (RNA-seq based omic:
2.25:1, and qRT-PCR analysis: 1.92:1, Fig. 1A and B).
To demonstrate its role in the BCa chemoresistance, we suppressed
the PSEN1 expression in 5637 cells by siRNA (Fig. 1D) and found that
the cell death triggered by each of the ﬁve drugs (paclitaxel, Pa;
adriamycin, Ad; cisplatin, Ci; pirarubicin, Pi; epirubicin hydrochloride,
EH) were suppressed in the PSEN1 siRNA transfected 5637 cells
(Fig. 1E). Conversely, an over-expressed GFP-tagged PSEN1 protein
(by Western analysis, Fig. 1F and an immunoﬂuorescence analysis,EN1 level in 5637 versus H-bc cells, atmRNA level (by themiR-seq and qRT-PCR analyses)
ein level). D, the level of the PSEN1mRNA (by qRT-PCR) and protein (byWestern analysis)
637 cells transfectedwith the PSEN1 over the NC siRNAs, assayed at 72 h post-treatment of
nstruct transfectedH-bc cells,measured byWestern analysis. G, the relative cell survival of
post-treatment of the IC50 dosed drugs. (*, P b 0.05;**, P b 0.01).
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Pa (Fig. 1G).
3.2. The PSEN1 is a direct target of miR-193a-3p in BCa cells
MiR-193a-3p has been noted for its role in the multi-
chemoresistance in both HCC [19] and BCa cells [20–22]. The miR-
193a-3p level is signiﬁcantly lower in 5637 than inH-bc, while its target
genes SRSF2, HIC2 and PLAU levels are lower in H-bc than 5637 cells
[20], a same expression pattern of the PSEN1 gene in the context of
the multi-chemoresistance of BCa (Fig. 1A).
Incidentally, miR-193a-3p is one of 56miRs that are bioinformatically
capable by the TargetScan software (http://www.targetscan.org/) of
repressing the PSEN1 gene expression at the post-transcriptional
level. To check the PSEN1 status as one of the miR-193a-3p's targets, we
determined the PSEN1 level in the miR-193a-3p mimic transfected
5637 and the antagomiR transfected H-bc cells versus the scramble se-
quence control (NC) transfected. Following the changes of the miR-
193a-3p level (up to roughly 4000 folds bymimic and 0.4% by antagomiR
relative to the NC, Fig. 2A), the miR-193a-3p mimic transfection brought
down the PSEN1mRNA to 52% (Fig. 2B) and the protein to 88% (Fig. 2C) of
the NC transfected 5637 cells. As expected, a miR-193a-3p antagomiRFig. 2. The PSEN1mRNA is a direct target ofmiR-193a-3p in BCa cells. The level ofmiR-193a-3p
themiR-193a-3pmimic (3PM) transfected 5637 cells and themiR-193a-3p antagomiR (3PA) tr
(thewild-type in shadow andmutant in red) in the 3′-UTR region of PSEN1 gene. E, the relative
orwithout UTR (Vec) were determined in themiR-193a-3pmimic (3PM) in 5637 or antagomiR
co-transfected reporter construct was used to control the transfection efﬁcacy. A representative
**P b 0.01; by Student's t-test.transfection raised the mRNA level of PSEN1 by roughly 5 folds (Fig. 2B)
and the protein level by 147% of the NC level in H-bc cells (Fig. 2C).
To concludewhether the PSEN1 is a direct target ofmiR-193a-3p,we
put the full length wild type or mutant 3′-untranslated region (UTR)
mega) to create pGL3-PSEN1 UTR WT or the PGL3-PSEN1 UTR Mut
(Fig. 2D). Both constructs and pGL3-control were transfected into
5637 andH-bc cells, respectively, to determinewhether thedifferential-
ly expressed miR-193a-3p in the context of the chemoresistance BCa
cells is really functional. pGL3-PSEN1-UTR WT but none of other two
reporter constructs gave a signiﬁcantly higher luciferase activity in
5637 than in H-bc cells (Fig. 2E, upper panel). Furthermore, the lucifer-
ase activity of pGL3-PSEN1-UTR WT but not other two was brought
down in the mimic transfected 5637 cells and raised in the antagomiR
transfected H-bc cells (Fig. 2E, middle and lower panels).
Following the changes of the PSEN1 protein level in both the miR-
193a-3p mimic and PSEN1 siRNA transfected 5637 cells (Fig. 3A), the
cell death triggered by all ﬁve drugs was reduced (Fig. 3B). Conversely,
a transfection of the GFP-tagged PSEN1 expression construct raised the
PSEN1 protein level (Fig. 3C), sensitized H-bc cells to Ad, Pi, or EH
(Fig. 3D). In line with its negative effect on chemoresistance (Fig. 1D
and F), a siRNA mediated PSEN1 repression reduced the apoptotic cells
from 2.35% to 1.36%, an effect that was not seen in the mimic transfected(A, by qRT-PCR), the PSEN1mRNA (B, by qRT-PCR) and protein (C, byWestern analysis) in
ansfectedH-bc cells versus the negative control (NC). D, themiR-193a-3p target sequences
luciferase activity (fold) of the reporter with wild-type (WT) ormutant (Mut) PSEN1-UTR
(3PA) in H-bc versusMock (NC) transfected BCa cells. The Renilla luciferase activity of the
result from three independent experiments shown. Error bars represent s.e.m. *P b 0.05;
Fig. 3. PSEN1's effects on the drug-triggered cell death in BCa cells is partially reproduced by a forced alteration ofmiR-193a-3p level in cells. A, the PSEN1 protein level (Western analysis)
in the 3PMor siRNA transfected versus the NC transfected 5637 cells. B, the relative cell survival of the 5637 cells transfectedwithmiR-193a-3pmimic (3PM) over theNC transfected 5637
cells, 72 h after a treatment of the IC50 dosed drugs. C, the PSEN1 protein level (Western analysis) in the 3PA or GFP tagged overexpression construct transfected versus the NC transfected
H-bc cells. D, the relative cell survival of the H-bc cells transfectedwithmiR-193a-3p antagomiR (3PA) over the NC transfected H-bc cells, assayed at 72 h post-treatment of the IC50 dosed
drugs. E, the effects of the forced reversal of both miR-193a-3p and PSEN1 levels on the apoptosis of 5637 cells by FACS analysis in plot and in the original. NB, *, P value b 0.05; **, P
value b 0.01.
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the PSEN1 gene seems to have a negative role opposite to the miR-193a-
3p's positive effect on the multi-chemoresistance of BCa cells. Getting
all these observations together, PSEN1 executes to a great extent the
miR-193a-3p's effect on the BCa chemoresistance to all ﬁve drugs
according to the results in the transfected 5637 cells (Figs. 1E and
3 B) or the following three drugs: Ad, Pi and EH according to the results
in the transfected H-bc cells (Figs. 1G and 3D).
3.3. PSEN1 positively regulates the DNA damage response pathway in the
context of BCa multi-chemoresistance
We recently showed that miR-193a-3p regulates the multi-
chemoresistance via repressing three of its downstream targets:
SRSF2, PLAU and HIC2 and in turn altering the activities of following
ﬁve signaling pathways: DNA damage response, Notch, NF-κB, Myc/
Max and oxidative stress [20]. Therefore, we determined which of
these ﬁve pathways are also affected by the forced changes of PSEN1
level in both 5637 and H-bc cells. As shown in Fig. 4A, when the
PSEN1 level was repressed by either miR-193a-3p mimic or PSEN1
siRNA transfection (Fig. 3A), activities of the DNA damage response
and Myc/Max pathways were affected. For instance, the activity of the
DNA damage response pathway was reduced by PSEN1 siRNA to 85%
of the level in the NC transfected control, in contrast to 17% of the NC
level by the miR-193a-3p mimic. For the Myc/Max pathway, the
PSEN1 siRNA led to a greater repression than the miR-193a-3p mimic
(Fig. 4A).We further assessed the changes of themRNA levels of the fol-
lowing genes in 5637 cells transfected by the PSEN1 siRNA in compari-
son with the NC andmiR-193a-3pmimic: the downstream genes of the
Myc/Max pathway (TERT and ODC1) and of the DNA damage response
pathway (CDKN1A and EDN1) as well as threemembers of γ-secretase:
PSEN1/2 and APH1A by qRT-PCR analysis. Along with the reduction ofthe PSEN1 mRNA by miR-193a-3p mimic or PSEN1 siRNA, one of the
downstream targets of the Myc/Max pathway, ODC1 mRNA level was
reduced as expected. However, the PSEN1 siRNA raised the mRNAs of
the DNA damage response pathway targets rather than repressed by
the mimic in 5637 cells. One plausible explanation for this conﬂicting
observation is that the repression of these two downstream genes by
miR-193a-3p is not achieved via its repression of PSEN1 expression at
the post-transcriptional level (Fig. 4B). Intriguingly, miR-193a-3p
mimic transfection not only brought down the PSEN1 level, but also
PSEN2 and APH1A levels (Fig. 4B). A PSEN1 independent mechanism
may account for the seeming conﬂicting results in the context of BCa
multi-drug chemoresistance (Figs. 1–3).
We further compared the activities of these ﬁve pathways in the
H-bc cells transfected with a GFP-PSEN1 expression construct or a
GFP alone construct and (the expression of GFP-PSEN1 gene in the
transfected H-bc cells was shown in panel, Fig. 3C) and showed
that among the two pathways suggested by the tests in 5637 cells
(Fig. 4A), only the activity of the DNA damage response pathway
was raised drastically by both miR-193a-3p antagomiR and EGP-
PSEN1 (Fig. 4C). Therefore, the PSEN1's role to relay the miR-193a-
3p's effect on the BCa chemoresistance is principally accomplished
via its effect on the DNA damage response pathway.
3.4. PSEN1 expression was reduced in the miR-193a-3p agomiR injected
5637 tumor xenografts and raised in the antagomiR-injected H-bc tumor
xenografts
Recently, it has been shown that miR-193a-3p promotes the Pa
chemoresistance of BCa in tumor xenografts of nudemice via its repres-
sion of three of its targets in tumor tissues: SRSF2, PLAU and HIC2 [20].
In the present study, we semi-quantiﬁed by an immuno-histological
analysis of the levels of PSEN1 protein (Fig. 5) in the same set of the
Fig. 4.A forced altering of the PSEN1 level changes the activities of signaling pathways assayed by using a Qiagen™ pathway reporter system. A, The relative activities (mean± S.D.) of ﬁve
pathways in the PSEN1 siRNA ormiR-193a-3pmimic transfected versus theNC transfected 5637 cells. B, themRNA levels (qRT-PCR analysis) of the effective genes of theDNA damage and
Myc/Max pathways' and the components of the γ-secretase complex in themiR-193a-3pmimic or PSEN1 siRNA transfected 5637 cells. C, the relative activities (mean± S.D.) of ﬁve path-
ways in the EGFP-PSEN1 vector or miR-193s-3p antagmiR (3PA) transfected versus the NC transfected H-bc cells. NB, *, P value b 0.05.
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PBS. The intratumor injection of either miR-193a-3p's agomiR (into
5637)/antagomiR (intoH-bc tumor) indeed led to the expected changes
of the PSEN1 protein in the tumor tissues (Fig. 5). This observation
further supports the notion that PSEN1 gene has a role in the miR-
193a-3p's promoting effect in the Pa-chemoresistance of the BCa cells.
4. Discussion
Despite years of intensive research efforts, the questions such as
how many genes contribute to the multi-chemoresistance of cancer
and by what mechanisms remain elusive. Our previous works have
shown that the miR-193a-3p is a potent promoter of the multi-
chemoresistance in bothHCC [19] and BCa via repressing the expression
of its three downstream targets: SRSF2, PLAU andHIC2 [20]. For the new
protein-coding genes instrumental to the multi-chemoresistance of
BCa, we performed a comparative RNA-seq omic analysis of a multi-
chemosensitive (5637) and resistant (H-bc) cell lines and identiﬁed
a panel of genes that are differentially expressed, including the PSEN1
gene in this paper that exhibits a negative correlation with the
chemoresistance (Fig. 1). Both role and mechanisms of the PSEN1 gene
in the context of BCa chemoresistance were systematically addressed
in both cultured cells and tumor xenografts in nude mice. A forced re-
version of the PSEN1 level in 5637 cells suppressed the drug-triggeredcell death by each of the ﬁve drugs that are also affected by miR-193a-
3p in a same way (Figs. 1 and 3). We then showed that PSEN1 gene is
another direct target of miR-193a-3p and acts as a key executor of the
former's promoting effects on the BCa chemoresistance (Figs. 2–5)
PSEN1 encodes the catalytic subunit of γ-secretase, a full function of
which is required for an activation of the Notch pathway [29]. It has
been reported that PSEN1 elevates the expression of the multidrug
resistance gene, ABCC1/MRP1 through its positive effect on Notch sig-
naling [30], and the inhibitor of γ-secretase will signiﬁcantly enhance
the anti-tumor activity of docetaxel and relieved its resistance in breast
cancer by several different mechanisms [31]. The PSEN1's involvement
in the BCa multi-chemoresistance seems more complicated. Although
a siRNA mediated repression of the PSEN1 expression desensitized
5637 cells to the drug-triggered cell death (Fig. 3A) and reduced the ac-
tivity of the Notch pathway (Fig. 4A), which is opposite to the positive
effect of the miR-193a-3p mimic on the Notch pathway (Fig. 4A). The
functional γ-secretase is a four component complex consisting of
Presenilin (PSEN1/2), Nicastrin, Aph-1, and PSENEN (Pen-2) [29]. It is
intriguing to observe that while the transfection of PSEN1 siRNA only
suppressed the PSEN1 mRNA level, miR-193a-3p mimic also repressed
the expression of both PSEN2 and Aph-1 genes (Fig. 4B). Since both
PSEN2 and Aph-1 genes do not have the target sequence of miR-193a-
3p at the 3′-UTR region analyzed by Targetscan [www.targetscan.org]
and miRDB [http://mirdb.org/miRDB/] as well as both 5′-UTR and
Fig. 5. The PSEN1 level in themiR-193a-3p agomiR injected 5637 and themiR-193a-3p antagomiR injected H-bc tumor xenograft versus the NC injected tumor xenografts determined by
an immunohistochemical staining. The 5637 and H-bc tumor tissues from each group were ﬁxed on one slide and immunostained for indicated antibody, respectively. Levels of PSEN1
proteins in each group were determined by immunostaining and summarized in the table.
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miR-193a-3p's effect on BCa chemoresistance observed is probably
achieved by the mechanisms involving other targets of miR-193a-3p.
In addition, the classic connection of the PSEN1with theNotch pathway
[29], seems to have a little role in the BCa chemoresistance in the
present study (Fig. 6).Fig. 6. The working model for the miR-193a-3p's role in regulation of the chemoresistance of
negative regulation of the by DNA methylation regulated miR-193a-3p, positively correlate w
on the signaling pathways via its repression of SRSF2, HIC2 and PLAU (previous work) and PSEThere are reports for a positive regulatory loop between γ-secretase
and p53 (the master transcriptional factor for the DNA damage
response pathway), the former is capable to upregulate both level and
activity of p53 [32], at the same time to be transcriptionally repressed
by p53 [33–35]. The PSEN1 transcription is also under the control of
Ets1/2 transcription factors, removal of which from its promoterBCa. A, expression of SRSF2, HIC2, PLAU (CDDis paper) and PSEN1 (here) genes under the
ith the chemoresistance to four indicated chemotherapeutics. B, the miR-193a-3p's effect
N1 (this work). C, ﬁgure legend.
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with p53 and a transcriptional silencing of the PSEN1 gene [36]. The
PSEN1 mutations have been suggested capable to induce the p53-
dependent apoptosis, which is repressed by γ-secretase inhibitor [37,
38]. Indeed, a siRNAmediated repression of the PSEN1 gene suppressed
both cell apoptosis (Fig. 3) and the activity of the DNAdamage response
pathway (Fig. 4). The functional links between the PSEN1 gene and the
Myc/Max pathway may chieﬂy involved p53 as a critical mediator
within the ARF–Mdm2–p53 regulatory loop [39–41]. It is clear from
this study that among the ﬁve pathways controlled bymiR-193-3p cen-
tered axis in BCa multi-chemoresistance, the DNA damage response
pathway is only one that is negatively regulated by PSEN1 (Fig. 4A and
C, and summarized in Fig. 6). Further studies are needed for the detailed
mechanisms whereby PSEN1 regulates the BCa multi-chemoresistance.
It is also worthwhile exploring whether the observations described in
this report can be translated into the clinical practice for better chemo-
therapy of BCa.
5. Conclusion
We have previously shown the DNA methylation analysis of the
promoter region of the following 11 genes: SALL3, CFTR, ABCC6, HPR1,
RASSF1A, MT1A, RUNX3, ITGA4, BCL2, ALX4, MYOD1, DRM, CDH13,
BMP3B, CCNA1, RPRM, MINT1, and BRCA1, in urine sediments con-
ﬁrmed the existing diagnosis of 121 among 132 bladder cancer cases
(sensitivity, 91.7%) with 87% accuracy [42]. In this study, we demon-
strated that PSEN1 is a direct target of miR-193a-3p, and negatively
regulates the multi-chemoresistance of BCa by activation of the DNA
damage response pathway. Therefore, the DNA methylation state of
the miR-193a gene and expression state of both PSEN1 gene the DNA
damage response pathway associated genes in both cancer tissues and
urine sediments should be promising diagnostic targets for the guided
anti-bladder cancer chemotherapy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.12.014.
Acknowledgements
This work was supported by the National Natural Science Founda-
tion of China (81472638 and 30921140312 to JZ, 81171996 and
81272289 granted to CZ, 81200975 granted to YL), the Young Outstand-
ing Scholarship Foundation of Anhui Medical University (to YL) and
Wujieping Medical Foundation (No. 320.6750.13252 to CZ).
References
[1] J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, Estimates of world-
wide burden of cancer in 2008: GLOBOCAN 2008, Int. J. Cancer 127 (2010)
2893–2917.
[2] M. Burger, J.W. Catto, G. Dalbagni, H.B. Grossman, H. Herr, P. Karakiewicz, W.
Kassouf, L.A. Kiemeney, C. La Vecchia, S. Shariat, Epidemiology and risk factors of
urothelial bladder cancer, Eur. Urol. 63 (2) (2013) 234–241.
[3] H. von der Maase, L. Sengelov, J.T. Roberts, S. Ricci, L. Dogliotti, T. Oliver, M.J.
Moore, A. Zimmermann, M. Arning, Long-term survival results of a randomized
trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer, J. Clin. Oncol. 23
(2005) 4602–4608.
[4] J.S. Chang, P.N. Lara, C.-X. Pan, Progress in personalizing chemotherapy for bladder
cancer, Adv. Urol. 2012 (2012).
[5] R.R. Gordon, P.S. Nelson, Cellular senescence and cancer chemotherapy resistance,
Drug Resist. Updat. 15 (2012) 123–131.
[6] M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, P.
Martinez, N. Matthews, A. Stewart, P. Tarpey, Intratumor heterogeneity and
branched evolution revealed by multiregion sequencing, N. Engl. J. Med. 366
(2012) 883–892.
[7] J.J. Martin, O. Briz, M.J. Monte, A.G. Blazquez, R.I. Macias, Genetic variants in genes
involved in mechanisms of chemoresistance to anticancer drugs, Curr. Cancer
Drug Targets 12 (2012) 402–438.
[8] F. Li, G. Sethi, Targeting transcription factor NF-κB to overcome chemoresistance and
radioresistance in cancer therapy, Biochim. Biophys. Acta (BBA)— Rev. Cancer 1805
(2010) 167–180.[9] K.M. Capaccione, S.R. Pine, The Notch signaling pathway as a mediator of tumor sur-
vival, Carcinogenesis 34 (2013) 1420–1430.
[10] R. Abbotts, N. Thompson, S. Madhusudan, DNA repair in cancer: emerging targets
for personalized therapy, Cancer Manag. Res. 6 (2014) 77.
[11] M. Landriscina, F. Maddalena, G. Laudiero, F. Esposito, Adaptation to oxidative
stress, chemoresistance, and cell survival, Antioxid. Redox Signal. 11 (2009)
2701–2716.
[12] S. Ahmad, Platinum–DNA interactions and subsequent cellular processes controlling
sensitivity to anticancer platinum complexes, Chem. Biodivers. 7 (2010) 543–566.
[13] A. Sau, F. Pellizzari Tregno, F. Valentino, G. Federici, A.M. Caccuri, Glutathione trans-
ferases and development of new principles to overcome drug resistance, Arch.
Biochem. Biophys. 500 (2010) 116–122.
[14] E.M. Leslie, R.G. Deeley, S.P. Cole, Multidrug resistance proteins: role of P-
glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense, Toxicol. Appl.
Pharmacol. 204 (2005) 216–237.
[15] P. Borst, R. Evers, M. Kool, J. Wijnholds, A family of drug transporters: the multidrug
resistance-associated proteins, J. Natl. Cancer Inst. 92 (2000) 1295–1302.
[16] B. Tan, D. Piwnica-Worms, L. Ratner, Multidrug resistance transporters andmodula-
tion, Curr. Opin. Oncol. 12 (2000) 450–458.
[17] G. Jedlitschky, I. Leier, U. Buchholz, K. Barnouin, G. Kurz, D. Keppler, Transport of
glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded
conjugate export pump, Cancer Res. 56 (1996) 988–994.
[18] K. To, MicroRNA: a prognostic biomarker and a possible druggable target for
circumventing multidrug resistance in cancer chemotherapy, J. Biomed. Sci. 20
(2013) 1–19.
[19] K. Ma, Y. He, H. Zhang, Q. Fei, D. Niu, D. Wang, X. Ding, H. Xu, X. Chen, J. Zhu, DNA
methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma
to 5-ﬂuorouracil via repression of SRSF2 expression, J. Biol. Chem. 287 (2012)
5639–5649.
[20] H.D.L. Lv, Y. Li, C. Zhang, X. Liu, Q. Liu, D. Zhang, L. Wang, Y. Pu, H. Zhang, Y. He, Y.
Wang, Y. Yu, T. Yu, J. Zhu, The DNA methylation-regulated miR-193a-3p dictates
the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2
expression, Cell Death Dis. 5 (2014) e1402.
[21] H. Deng, L. Lv, Y. Li, C. Zhang, F. Meng, Y. Pu, J. Xiao, L. Qian, W. Zhao, Q. Liu, D. Zhang,
Y. Wang, H. Zhang, Y. He, J. Zhu, miR-193a-3p regulates the multi-drug resistance of
bladder cancer by targeting the LOXL4 gene and the Oxidative Stress pathway, Mol
Cancer 13 (2014) 234.
[22] L. Lv, Y. Li, H. Deng, C. Zhang, Y. Pu, L. Qian, J. Xiao,W. Zhao, Q. Liu, D. Zhang, Y.Wang,
H. Zhang, Y. He, J. Zhu, MiR-193a-3p promotes the multi-chemoresistance of blad-
der cancer by targeting the HOXC9 gene, Cancer Lett. (2014) pii: S0304-
3835(14)00656-9.
[23] A. Brunkan, A. Goate, Presenilin function and γ‐secretase activity, J. Neurochem. 93
(2005) 769–792.
[24] L. Bertram, C.M. Lill, R.E. Tanzi, The genetics of Alzheimer disease: back to the future,
Neuron 68 (2010) 270–281.
[25] L. Chávez‐Gutiérrez, L. Bammens, I. Benilova, A. Vandersteen, M. Benurwar, M.
Borgers, S. Lismont, L. Zhou, S. Van Cleynenbreugel, H. Esselmann, The mechanism
of γ‐secretase dysfunction in familial Alzheimer disease, EMBO J. 31 (2012)
2261–2274.
[26] J. Li, F. Chen, M.M. Cona, Y. Feng, U. Himmelreich, R. Oyen, A. Verbruggen, Y. Ni,
A review on various targeted anticancer therapies, Target. Oncol. 7 (2012)
69–85.
[27] L.M. Heiser, A. Sadanandam, W.L. Kuo, S.C. Benz, T.C. Goldstein, S. Ng, W.J. Gibb, N.J.
Wang, S. Ziyad, F. Tong, N. Bayani, Z. Hu, J.I. Billig, A. Dueregger, S. Lewis, L. Jakkula,
J.E. Korkola, S. Durinck, F. Pepin, Y. Guan, E. Purdom, P. Neuvial, H. Bengtsson, K.W.
Wood, P.G. Smith, L.T. Vassilev, B.T. Hennessy, J. Greshock, K.E. Bachman, M.A.
Hardwicke, J.W. Park, L.J. Marton, D.M. Wolf, E.A. Collisson, R.M. Neve, G.B. Mills,
T.P. Speed, H.S. Feiler, R.F. Wooster, D. Haussler, J.M. Stuart, J.W. Gray, P.T.
Spellman, Subtype and pathway speciﬁc responses to anticancer compounds in
breast cancer, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 2724–2729.
[28] L. Dou, J. Li, D. Zheng, Y. Li, X. Gao, C. Xu, L. Gao, L. Wang, L. Yu, MicroRNA-205
downregulates mixed-lineage-AF4 oncogene expression in acute lymphoblastic
leukemia, Oncol. Targets Ther. 6 (2013) 1153.
[29] B. De Strooper, Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-
secretase complex, Neuron 38 (2003) 9–12.
[30] S. Cho, M. Lu, X. He, P.-L.R. Ee, U. Bhat, E. Schneider, L. Miele, W.T. Beck, Notch1
regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured
cancer cells, Proc. Natl. Acad. Sci. 108 (2011) 20778–20783.
[31] C.C. Zhang, Z. Yan, Q. Zong, D.D. Fang, C. Painter, Q. Zhang, E. Chen, M.E. Lira, A.
John-Baptiste, J.G. Christensen, Synergistic effect of the γ-secretase inhibitor
PF-03084014 and docetaxel in breast cancer models, Stem Cells Transl. Med. 2
(2013) 233–242.
[32] C.A. da Costa, C. Sunyach, R. Pardossi-Piquard, J. Sévalle, B. Vincent, N. Boyer, T.
Kawarai, N. Girardot, P.S. George-Hyslop, F. Checler, Presenilin-dependent γ-
secretase-mediated control of p53-associated cell death in Alzheimer's disease, J.
Neurosci. 26 (2006) 6377–6385.
[33] F. Checler, J. Dunys, R. Pardossi-Piquard, C. Alves da Costa, p53 is regulated by
and regulates members of the γ-secretase complex, Neurodegener. Dis. 7 (2010)
50–55.
[34] J. Dunys, J. Sevalle, E. Giaime, R. Pardossi-Piquard, M.P. Vitek, P. Renbaum, E. Levy-
Lahad, Y.-w. Zhang, H. Xu, F. Checler, p53-dependent control of transactivation of
the Pen2 promoter by presenilins, J. Cell Sci. 122 (2009) 4003–4008.
[35] J. Dunys, T. Kawarai, J. Sevalle, V. Dolcini, P.S. George-Hyslop, C.A. Da Costa, F.
Checler, p53-dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the in-
tegrity of the γ-secretase complex but is independent of its activity, J. Biol. Chem.
282 (2007) 10516–10525.
528 H. Deng et al. / Biochimica et Biophysica Acta 1852 (2015) 520–528[36] S. Lee, H.K. Das, Inhibition of basal activity of c-biNjunb/iN-NH2-terminal kinase
(JNK) represses the expression of presenilin-1 by a p53-dependent mechanism,
Brain Res. 1207 (2008) 19–31.
[37] K. Miyoshi, Y. Ohyagi, N. Sakae, K. Motomura, L. Ma, T. Taniwaki, H. Furuya, T. Tabira,
J.-i. Kira, Enhancement of activation of caspases by presenilin 1 gene mutations
and its inhibition by secretase inhibitors, J. Alzheimers Dis. 16 (2009)
551–564.
[38] L. Ma, Y. Ohyagi, K. Miyoshi, N. Sakae, K. Motomura, T. Taniwaki, H. Furuya, K.
Takeda, T. Tabira, J.-i. Kira, Increase in p53 protein levels by presenilin 1 genemuta-
tions and its inhibition by secretase inhibitors, J. Alzheimers Dis. 16 (2009)
565–575.[39] B. Hoffman, D. Liebermann, Apoptotic signaling by c-MYC, Oncogene 27 (2008)
6462–6472.
[40] J.S. Ho, W. Ma, D.Y. Mao, S. Benchimol, p53-Dependent transcriptional repression of
c-myc is required for G1 cell cycle arrest, Mol. Cell. Biol. 25 (2005) 7423–7431.
[41] C.J. Sherr, Divorcing ARF and p53: an unsettled case, Nat. Rev. Cancer 6 (2006)
663–673.
[42] J. Yu, T. Zhu, Z. Wang, H. Zhang, Z. Qian, H. Xu, B. Gao, W. Wang, L. Gu, J. Meng, J.
Wang, X. Feng, Y. Li, X. Yao, J. Zhu, A novel set of DNA methylation markers in
urine sediments for sensitive/speciﬁc detection of bladder cancer, Clin. Cancer Res.
13 (2007) 7296–7304.
